Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas
Dr. Barakat is the leader of a multidisciplinary world-class research team to develop novel immunotherapy drugs targeting the immune checkpoints' proteins. He received his PhD in biophysics from the University of Alberta in 2012 followed by a postdoctoral fellowship in Professor Michael Houghton’s Lab for two years. During his career, Dr. Barakat received numerous awards including the CIHR and AIHS postdoctoral fellowships, the prestigious UofA dissertation award, the ACRI Studentship and many distinction awards throughout his undergraduate and graduate studies. Dr. Barakat is also the editor of a number of journals. Dr. Barakat's lab is supported by different funding agencies including the Alberta Cancer Foundation, Li Ka Shing Applied Virology Institute, Natural Sciences and Engineering Research Council (NSERC), Li Ka Shing Institute of Virology and IC-IMPACTS Centres of Excellence.
Microbiology and Virology
Dr Hosni Sassi is Faculty of Sciences at Université libre de Bruxelles, Belgium
Steve Projan is the head of Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area strategy, prioritization and advancement of the company’s infectious disease and vaccine portfolio. Steve joined MedImmune in 2010 as senior vice president of research and development and head of the Infectious Diseases & Vaccines iMED. Prior to joining MedImmune, Steve served as vice president and global head of Infectious Diseases at Novartis. He previously spent 15 years at Wyeth in roles of increasing responsibility, with his last post as vice president and head of Biological Technologies. During his time at Wyeth, he started the Biologics Discovery Group (covering all therapeutic areas) and initiated multiple collaborations and partnerships, most notably with Cambridge Antibody Technology (now a part of MedImmune/AZ). Prior to his work in the industry, Steve spent 14 years at the Public Health Research Institute and presently has over 110 publications to his credit. Steve received a bachelor of science from MIT, and, from Columbia University, a master of arts and philosophy in biological sciences and a doctorate in molecular genetics.
Infectious diseases and vaccines
Frederic Bibollet-Ruche is Research Assistant Professor of Medicine at PERELMAN SCHOOL OF MEDICINE
Akira Kaji is a professor of microbiology, School of Medicine, University of Pennsylvania. He contributed to the deciphering of genetic code by his discovery of the fact that the complex of poly-U with ribosome binds specifically tRNA specific for phenylalanine. He also discovered RRF.
Dr. Fernando de la Calle holds an Executive MBA (2005) and Ph.D in Molecular Microbiology from the Universidad Autónoma de Madrid (1998). He joined PharmaMar, Spanish company involved in advancing cancer care through the discovery and development of marine derived drugs, in 1988. Since 1999, he has had been Head of the Marine Microbiology R&D Department. The activities of his research group are focused on the study of the marine microorganisms as potential producers of antitumor compounds (drug discovery) and the design of biotechnological processes to supply drug substances. Fernando has been one of the authors of the current manufacturing process of Yondelis, a marine derived compound recently approved by the EMEA (European Union) for the treatment of soft- tissue sarcomas (2007) and recurrent ovarian cancer in combination with Caelyx® (2009).
Microbiology, Cancer and Drug discovery
Dr Pankaj Mehrotra did Doctor of Philosophy in Medical Sciences (Science) from University of Aberdeen, Scotland. And is a member of various international microbiology societies. He have also received invitations to deliver guest lectures, to teach distance education courses and examiner for undergraduate courses by Indian and American University.He have currently published more than 12 articles in international journals.
Zoology, biological sciences, Genetics and Microbiology
Dr Maulin Shah is Ph.D in Microbiology and is currently working as Chief Scientist & Head-Industrial Waste Water Research Lab, Enviro Technology Limited, Ankleshwar, India
Microbiology and water Microbiology
Mohemid M. Al-Jebouri is Professor in Department of Microbiology, College of Medicine, University of Tikrit, Tikrit, Iraq.
Infetcious Diseases,Pharmaceutical Microbiology,Allergy and Immunity,Clinical Diagnosis and Management by Laboratory Methods.
Dr Drouin Pascal is presently working as Research Manager in Lallemand Inc department of Animal Nutrition, United States